Abstract
Aporphinoid alkaloids, which encompass a large number of complicated structures, are an important group of natural products. The anticancer activity of aporphinoid alkaloids has become a hot pharmaceutical research area in recent years. Recent studies on the anticancer activity of these compounds are reviewed. The structure activity relationships (SARs) and anticancer mechanisms of aporphinoid alkaloids, as well as simple aporphine, oxoaporphine, dehydroaporphine and dimeric aporphine, have been summarized. The presence of a 1,2-methylenedioxy group and methylation of nitrogen are key features to the cytotoxicity of aporphinoid alkaloids. Oxidation and dehydrogenation of C7 could improve the anticancer activity. The contributions of chirality of hydrogen at C6a and the substitution pattern of other positions about aporphinoid alkaloids for anticancer activity remain unknown. Induced cancer cells apoptosis, prevention of cell proliferation, DNA topoisomerase inhibition, reducing the drug-resistant cellular side population (SP) or cancer stem cells (CSCs) and inhibition of epidermal growth factor receptor (EGFR) tyrosine kinase seem to play important roles in the molecular mechanisms of anticancer activity about aporphinoid alkaloids.
Keywords: Natural product, Aporphinoid alkaloids, Chemical structure, Anticancer activity, Apoptosis, SARs.
Current Topics in Medicinal Chemistry
Title:Structural and Mechanistic Bases of the Anticancer Activity of Natural Aporphinoid Alkaloids
Volume: 13 Issue: 17
Author(s): Yanjuan Liu, Junxi Liu, Duolong Di, Min Li and Yan Fen
Affiliation:
Keywords: Natural product, Aporphinoid alkaloids, Chemical structure, Anticancer activity, Apoptosis, SARs.
Abstract: Aporphinoid alkaloids, which encompass a large number of complicated structures, are an important group of natural products. The anticancer activity of aporphinoid alkaloids has become a hot pharmaceutical research area in recent years. Recent studies on the anticancer activity of these compounds are reviewed. The structure activity relationships (SARs) and anticancer mechanisms of aporphinoid alkaloids, as well as simple aporphine, oxoaporphine, dehydroaporphine and dimeric aporphine, have been summarized. The presence of a 1,2-methylenedioxy group and methylation of nitrogen are key features to the cytotoxicity of aporphinoid alkaloids. Oxidation and dehydrogenation of C7 could improve the anticancer activity. The contributions of chirality of hydrogen at C6a and the substitution pattern of other positions about aporphinoid alkaloids for anticancer activity remain unknown. Induced cancer cells apoptosis, prevention of cell proliferation, DNA topoisomerase inhibition, reducing the drug-resistant cellular side population (SP) or cancer stem cells (CSCs) and inhibition of epidermal growth factor receptor (EGFR) tyrosine kinase seem to play important roles in the molecular mechanisms of anticancer activity about aporphinoid alkaloids.
Export Options
About this article
Cite this article as:
Liu Yanjuan, Liu Junxi, Di Duolong, Li Min and Fen Yan, Structural and Mechanistic Bases of the Anticancer Activity of Natural Aporphinoid Alkaloids, Current Topics in Medicinal Chemistry 2013; 13 (17) . https://dx.doi.org/10.2174/15680266113139990147
DOI https://dx.doi.org/10.2174/15680266113139990147 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurosteroids and Hepatic Encephalopathy: An Update on Possible Pathophysiologic Mechanisms
Current Molecular Pharmacology Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets Importance of Aquaporins in the Physiopathology of Brain Edema
Current Pharmaceutical Design Recent Progress in Polynuclear Ruthenium Complex-Based DNA Binders/Structural Probes and Anticancer Agents
Current Medicinal Chemistry Hemichannels in the Neurovascular Unit and White Matter Under Normal and Inflamed Conditions
CNS & Neurological Disorders - Drug Targets Antitumor Effects of Celastrol and Semi-Synthetic Derivatives
Mini-Reviews in Organic Chemistry Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy An Overview of Nanoformulated Nutraceuticals and their Therapeutic Approaches
Current Nutrition & Food Science Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Rate Limiting Steps of AAV Transduction and Implications for Human Gene Therapy
Current Gene Therapy Targeting βIII-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Potential Impacts of Prebiotics and Probiotics on Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
Current Pharmaceutical Design Effective Treatment of Human Lung Cancer by Targeting Tissue Factor with a Factor VII-Targeted Photodynamic Therapy
Current Cancer Drug Targets TGFß, a Potent Regulator of Tumor Microenvironment and Host Immune Response, Implication for Therapy
Current Molecular Medicine Purinergic Signaling and Energy Homeostasis in Psychiatric Disorders
Current Molecular Medicine Immune System Modulates the Function of Adult Neural Stem Cells
Current Immunology Reviews (Discontinued) The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Transductional Targeting with Recombinant Adenovirus Vectors
Current Gene Therapy